Articles from Dianthus Therapeutics, Inc.

Phase 2 MaGic trial of DNTH103 in generalized Myasthenia Gravis (gMG) ongoing; top-line results on track for 2H’25

Mr. King launched the first approved biologic and C5 complement inhibitor into the Myasthenia Gravis market and helped set the foundation for the multi-billion dollar C5 franchise of Alexion

NEW YORK and WALTHAM, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the company’s participation at the following investor conferences:

NEW YORK and WALTHAM, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the company’s participation and presentations by Marino Garcia, Chief Executive Officer, at the following healthcare investor conferences during the month of February:

NEW YORK and WALTHAM, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the company’s participation at the 43rd Annual J.P. Morgan Healthcare Conference. Marino Garcia, Chief Executive Officer, will present a corporate overview on Wednesday, January 15, 2025 at 9:00 a.m. PST / 12:00 p.m. EST in San Francisco.

Initiation of a single, two-part, pivotal Phase 3 trial of DNTH103 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) anticipated by YE’24

NEW YORK and WALTHAM, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the company’s participation and corporate overview presentations by Marino Garcia, Chief Executive Officer, at the following healthcare investor conferences during November and December 2024:

NEW YORK and WALTHAM, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced two poster presentations for DNTH103 at the 2024 American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting, taking place October 15-18, 2024 in Savannah, Georgia.

NEW YORK and WALTHAM, Mass., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the company’s participation and corporate overview presentations by Marino Garcia, Chief Executive Officer, at the following healthcare investor conferences during the month of September:

Phase 2 MaGic trial in generalized Myasthenia Gravis (gMG) ongoing; top-line results anticipated in 2H’25

NEW YORK and WALTHAM, Mass., June 28, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced two poster presentations for DNTH103 at the 10th Congress of the European Academy of Neurology (EAN), taking place June 29-July 2, 2024 in Helsinki.

Top-line results from Phase 2 MoMeNtum trial in Multifocal Motor Neuropathy anticipated in 2H 2026

NEW YORK and WALTHAM, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced its participation in the Jefferies Global Healthcare Conference. Marino Garcia, Chief Executive Officer, will present a corporate overview on Thursday, June 6, 2024 at 1:30 p.m. ET in New York.

Phase 2 MaGic trial in generalized Myasthenia Gravis (gMG) ongoing, with top-line results anticipated in 2H’25

NEW YORK and WALTHAM, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced its participation in the Bank of America Securities 2024 Health Care Conference. Marino Garcia, Chief Executive Officer, will present a corporate overview on Tuesday, May 14, 2024 at 4:20 p.m. PT in Las Vegas.

NEW YORK and WALTHAM, Mass., May 03, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (“Dianthus”), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced that it granted equity awards on May 1, 2024, to two newly-hired, non-executive employees. The inducement grants were approved by the Company's independent Compensation Committee and were made as material inducements to acceptance of employment with Dianthus in accordance with Nasdaq Listing Rule 5635(c)(4).

NEW YORK and WALTHAM, Mass., April 11, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced an oral presentation for DNTH103 at the American Academy of Neurology (AAN) Annual Meeting, taking place April 13-18, 2024 in Denver, Colorado and virtually.

NEW YORK and WALTHAM, Mass., April 05, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (“Dianthus”), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced that it granted equity awards on April 1, 2024, to six newly-hired, non-executive employees. The inducement grants were approved by the Company's independent Compensation Committee and were made as material inducements to acceptance of employment with Dianthus in accordance with Nasdaq Listing Rule 5635(c)(4).

NEW YORK and and WALTHAM, Mass., March 07, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH) (“Dianthus”), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced that it granted an equity award on March 2, 2024, to a newly-hired, non-executive employee. The inducement grant was approved by the Company's independent Compensation Committee and was made as a material inducement to acceptance of employment with Dianthus in accordance with Nasdaq Listing Rule 5635(c)(4).

Top-line results from gMG MaGic trial anticipated in 2H 2025

NEW YORK and WALTHAM, Mass., Feb. 23, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced its participation in the TD Cowen 44th Annual Health Care Conference. Marino Garcia, Chief Executive Officer, will present a corporate overview on Monday, March 4, 2024, at 2:50 p.m. EST in Boston.

NEW YORK and WALTHAM, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced that members of the Company’s senior management team will participate in a fireside chat at the Guggenheim 6th Annual Biotechnology Conference on February 7, 2024, at 10:30 a.m. EST in New York City.

NEW YORK and WALTHAM, Mass., Jan. 22, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (“Dianthus” or the “Company”) (NASDAQDNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced that it has entered into a securities purchase agreement for a private investment in public equity (“PIPE”) financing that is expected to result in gross proceeds of approximately $230 million to the Company, before deducting placement agent fees and offering expenses. The PIPE financing included participation from both new and existing investors, including Bain Capital Life Sciences, RA Capital Management, Avidity Partners, Fairmount, Venrock Healthcare Capital Partners, RTW Investments, Great Point Partners LLC, Octagon Capital, Janus Henderson Investors, Vestal Point Capital, Logos Capital, Catalio Capital Management, Woodline Partners LP, Ally Bridge Group, Tellus BioVentures, StemPoint Capital LP and a large investment management firm. 

NEW YORK and WALTHAM, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced its participation in the 42nd Annual J.P. Morgan Healthcare Conference. Marino Garcia, Chief Executive Officer, will present a corporate overview on Thursday, January 11, 2024, at 10:30 a.m. PST / 1:30 p.m. EST in San Francisco, California.

NEW YORK and WALTHAM, Mass., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (“Dianthus”), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced that it granted an equity award on December 1, 2023 as a material inducement to employment of the newly-hired Chief Scientific Officer, Jeffrey Stavenhagen, Ph.D. The inducement grant was approved by the Company's independent Compensation Committee and was made as a material inducement to Dr. Stavenhagen’s acceptance of employment with Dianthus in accordance with Nasdaq Listing Rule 5635(c)(4).

Dr. Stavenhagen brings over 20 years of experience in leading drug discovery initiatives, with a focus on monoclonal antibodies targeting neuro diseases

Began trading on Nasdaq under the ticker symbol DNTH following the successful completion of our merger with Magenta Therapeutics

NEW YORK and WALTHAM, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics, today announced that the Company’s senior management team will participate in the following upcoming investor healthcare conferences during the month of November:

Positive top-line Phase 1 data for lead clinical program DNTH103 confirm potent classical pathway inhibition, extended half-life, and a potentially differentiated safety profile

The combined company will operate as “Dianthus Therapeutics, Inc.” with its common stock traded on Nasdaq under trading symbol “DNTH” effective Tuesday, September 12, 2023